DRRX - デュレクト (DURECT Corporation) デュレクト

 DRRXのチャート


 DRRXの企業情報

symbol DRRx
会社名 Durect Corp (デュレクト)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダレクト(Durect Corporation)は研究と開発に従事するバイオ医薬企業である。同社の候補製品は代謝/脂質障害向けの経口薬DUR-928、急性臓器傷害の注射可能薬DUR-928を含む。同社の他の製品候補はPOSIMIR(ブピバカインの制御放出注入)、REMOXY(経口制御放出オキシコドン)、ORADUR-ADHD、ELADUR(経口制御放出オキシコドン)、Relday(リスペリドン)、ORADURベースのオピオイド(ヒドロモルホン)、SABREベースの眼科薬を含む。同社のALZET製品ラインはマウス、ラットおよび他の実験動物の研究に使用される小型の移植可能な浸透圧ポンプと付属品を提供する。同社は製薬と医療機器クライアントの製品原材料に応用する標準およびカスタム生分解性ポリマーと賦形剤の生産と販売を行う。   デュレクトは米国の医薬品会社。慢性痛、術後疼痛、統合失調症、躁うつ症、注意欠陥多動性障害の治療薬に焦点を置く。「レモキシ―(経口オキシコドン)」、「ポジデュア(ブピバカイン注射剤)」、「エラデュア(経皮吸収ブピバカイン)」、リスペリドン系抗精神病薬、「オラデュア」の治験を行う。  DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
本社所在地 10260 Bubb Road Cupertino CA 95014 USA
代表者氏名 Felix D Theeuwes フェリックス・テューウィーズ
代表者役職名 Chairman Chief Scientific Officer
電話番号 +1 408-777-1417
設立年月日 35827
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数
url www.durect.com
nasdaq_url https://www.nasdaq.com/symbol/drrx
adr_tso
EBITDA EBITDA(百万ドル) 0.69000
終値(lastsale) 1.07
時価総額(marketcap) 173341767.64
時価総額 時価総額(百万ドル) 168.48170
売上高 売上高(百万ドル) 47.18500
企業価値(EV) 企業価値(EV)(百万ドル) 145.94370
当期純利益 当期純利益(百万ドル) -0.96200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 DURECT Corporation revenues decreased 22% to $6.9M. Net loss decreased 15% to $15.3M. Revenues reflect Product Revenues net decrease of 28% to $5.2M. Lower net loss reflects Other Research and development decrease of 22% to $12.4M (expense) Selling and general decrease of 13% to $5.4M (expense) Interest and other income increase from $75K to $398K (income).

 DRRXのテクニカル分析


 DRRXのニュース

   DURECT Co. (NASDAQ:DRRX) Shares Purchased by Charles Schwab Investment Management Inc.  2021/11/30 10:56:41 Dakota Financial News
Charles Schwab Investment Management Inc. increased its stake in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 573,991 shares of the specialty pharmaceutical companys stock after purchasing an additional 26,288 shares during the period. Charles []
   DURECT Co. (NASDAQ:DRRX) Stock Position Trimmed by California State Teachers Retirement System  2021/11/30 10:14:44 Dakota Financial News
California State Teachers Retirement System cut its position in DURECT Co. (NASDAQ:DRRX) by 7.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 312,482 shares of the specialty pharmaceutical companys stock after selling 23,890 shares during the quarter. California State Teachers Retirement Systems holdings in DURECT were worth $509,000 as of its most recent filing []
   Nuveen Asset Management LLC Sells 64,997 Shares of DURECT Co. (NASDAQ:DRRX)  2021/11/26 09:54:41 Transcript Daily
Nuveen Asset Management LLC cut its stake in shares of DURECT Co. (NASDAQ:DRRX) by 6.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 932,510 shares of the specialty pharmaceutical companys stock after selling 64,997 shares during the quarter. Nuveen Asset Management LLC []
   DURECT Co. (NASDAQ:DRRX) Shares Sold by MetLife Investment Management LLC  2021/11/24 10:34:41 Dakota Financial News
MetLife Investment Management LLC decreased its position in shares of DURECT Co. (NASDAQ:DRRX) by 74.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,530 shares of the specialty pharmaceutical companys stock after selling 69,869 shares during the period. MetLife Investment Management []
   Data-Based Insights About DURECT Corporation (DRRX)  2021/11/19 15:00:00 Stocks Register
DURECT Corporation (NASDAQ:DRRX) price on Thursday, November 18, rose 1.80% above its previous days close as an upside momentum from buyers pushed the stocks value to $1.13. A look at the stocks price movement, the close in the last trading session was $1.11, moving within a range at $1.10 and $1.19. The beta value (5-Year Data-Based Insights About DURECT Corporation (DRRX) Read More »
   DURECT Co. (NASDAQ:DRRX) Expected to Announce Earnings of -$0.04 Per Share  2021/10/29 15:18:46 Transcript Daily
Equities analysts expect DURECT Co. (NASDAQ:DRRX) to announce earnings of ($0.04) per share for the current quarter, according to Zacks. Two analysts have made estimates for DURECTs earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.05). DURECT posted earnings of ($0.05) per share in the same []
   DURECT (DRRX) to Release Quarterly Earnings on Tuesday  2021/10/27 12:42:41 Dakota Financial News
DURECT (NASDAQ:DRRX) will issue its quarterly earnings data after the market closes on Tuesday, November 2nd. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. DURECT (NASDAQ:DRRX) last released its quarterly earnings results on Thursday, July 29th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, meeting []
   DURECT Corporation (NASDAQ:DRRX) Has Recovered -38.30 Percent This Year, But Further Gains Of -154.31% Are Not Out Of The Question.  2021/10/23 14:00:00 Marketing Sentinel
In last trading session, DURECT Corporation (NASDAQ:DRRX) saw 0.72 million shares changing hands with its beta currently measuring 1.19. Companys recent per share price level of $1.16 trading at -$0.01 or -0.85% at ring of the bell on the day assigns it a market valuation of $272.80M. That closing price of DRRXs stock is at DURECT Corporation (NASDAQ:DRRX) Has Recovered -38.30 Percent This Year, But Further Gains Of -154.31% Are Not Out Of The Question. Read More »
   $2.18 Million in Sales Expected for DURECT Co. (NASDAQ:DRRX) This Quarter  2021/10/20 02:00:41 Transcript Daily
Wall Street analysts predict that DURECT Co. (NASDAQ:DRRX) will post sales of $2.18 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for DURECTs earnings, with the highest sales estimate coming in at $2.35 million and the lowest estimate coming in at $2.00 million. DURECT posted sales of []
   Bioresorbable Medical Material Market to reach US$ 1,942.13 million by 2027 | Top Key Players Durect Corporation, Foster Corporation, Ashland, Corbion, Putnam Plastics  2021/09/03 13:42:10 OpenPR
According to The Insight Partners market research study of Bioresorbable Medical MaterialMarketto 2027 Global Analysis and Forecasts by Product Type andApplication. The report provides trends prevailing in the global bioresorbable medical materialmarketand the factors driving market along with those that
   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
   DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)  2021/06/09 00:00:00 BioSpace
DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26 , 2021.
   Willams Sundrome Market 2021 Industry Trends, Growth, Analysis, Opportunities And Overview:DURECT CORPORATION, Vallon Pharmaceuticals, BD  2021/05/19 09:36:22 OpenPR
Market analysis and market segmentation has been carried out to create Willams Sundrome Market report, in terms of markets, geographic scope, years considered for the study, currency and pricing, research methodology, primary interviews with key opinion leaders, DBMR market position
   Zacks: Analysts Anticipate DURECT Co. (NASDAQ:DRRX) Will Announce Earnings of -$0.05 Per Share  2021/05/11 08:56:44 Dakota Financial News
Brokerages forecast that DURECT Co. (NASDAQ:DRRX) will post earnings per share of ($0.05) for the current quarter, according to Zacks. Three analysts have issued estimates for DURECTs earnings, with estimates ranging from ($0.05) to ($0.04). DURECT reported earnings per share of $0.07 during the same quarter last year, which suggests a negative year-over-year growth rate []
   DURECT Corporation Shares Close the Week 21.9% Higher - Weekly Wrap  2021/02/05 22:30:00 Kwhen Finance
DURECT Corporation shares closed this week 21.9% higher than it did at the end of last week. The stock is currently up 23.7% year-to-date, up 61.0% over the past 12 months, and up 148.5% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 3.8%. Trading Activity Shares traded as high as $2.95 and as low as $2.35 this week.Shares closed 1e+1% below its 52-week high and 2e+2% above its 52-week low.Trading volume this week was 31.0% lower than the 10-day average and 71.7% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 220.2% The company's stock price performance over the past 12 months beats the peer average by 528.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デュレクト DRRX DURECT Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)